Research Article
The Relationship of Conduction Disorder and Prognosis in Patients with Acute Coronary Syndrome
Table 1
Baseline characteristics and clinical outcomes in the patients with and without conduction disorder.
| | | With conduction disorder | Without conduction disorder | -Value |
| | Number general demographics | 3392 | 30578 | | | Age (years) | 69 (13.6) | 66 (13.8) | <0.001 | | Male sex (%) | 2412 (71.11) | 21088 (68.96) | 0.010 | | BMI (kg/m2) | 24.84 (4.38) | 25.04 (4.39) | 0.024 |
| | Comorbidities | | Diabetes mellitus (%) | 1279 (37.71) | 11079 (36.23) | 0.090 | | Hypertension (%) | 1939 (57.16) | 17089 (55.89) | 0.155 | | PAOD (%) | 47 (1.39) | 213 (0.70) | <0.001 | | COPD (%) | 214 (6.31) | 1511 (4.94) | <0.001 | | ESRD (%) | 480 (14.15) | 2425 (7.93) | <0.001 | | Smoking (%) | 387 (11.41) | 4590 (15.01) | <0.001 | | Liver cirrhosis (%) | 44 (1.30) | 486 (4.59) | 0.193 | | Prior GI bleeding (%) | 407 (12.00) | 3180 (10.40) | 0.004 | | Prior stroke (%) | 227 (6.69) | 2085 (6.82) | 0.782 | | HF (%) | 1118 (32.96) | 7097 (23.21) | <0.001 | | Valvular heart disease (%) | 159 (5.99) | 1815 (8.13) | <0.001 |
| | Medication | | Antiplatelet agent | | | | | Aspirin (%) | 2032 (59.91) | 19709 (64.45) | <0.001 | | Clopidogrel (%) | 1596 (47.05) | 15684 (51.29) | <0.001 | | Ticagrelor (%) | 556 (16.39) | 4381 (14.33) | 0.001 | | Prasugrel (%) | 16 (0.47) | 145 (0.47) | 0.984 | | ACEI/ARB/Entresto (%) | 1727 (50.91) | 15972 (52.23) | 0.144 | | β-blocker (%) | 1890 (55.72) | 17340 (56.71) | 0.271 | | Diuretic (%) | 864 (25.47) | 5948 (19.45) | <0.001 | | Lipid-lowering agents (%) | 1784 (52.59) | 16329 (53.40) | 0.372 |
| | Left ventricular performance | | Mean LVEF (%) | 44.64 (20.73) | 49.85 (20.63) | <0.001 |
| | F/U period (years) | 1.8 (1.5) | 2.9 (2.6) | <0.001 |
|
|
Data are expressed as mean (standard deviation) or as number (percentage). Abbreviation: BMI: body mass index; PAOD: peripheral arterial occlusive disease; COPD: chronic obstructive pulmonary disease; ESRD: end-stage renal disease; GI: gastrointestinal; HF: heart failure; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; MRA: mineralocorticoid receptor antagonist; LVEF: left ventricular ejection fraction; F/U: follow-up.
|
